Recent breakthroughs in targeting the RAS oncogene began with KRAS-G12C inhibition, which has shown some promise in phase I/II clinical trials for metastatic lung, pancreatic, and colorectal carcinomas (25–28). Here, KRAS is linked to colorectal carcinoma.